Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Published:2019-05 Issue:5 Volume:20 Page:636-648
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moore Kathleen N,Secord Angeles Alvarez,Geller Melissa A,Miller David Scott,Cloven Noelle,Fleming Gini F,Wahner Hendrickson Andrea E,Azodi Masoud,DiSilvestro Paul,Oza Amit M,Cristea Mihaela,Berek Jonathan S,Chan John K,Rimel Bobbie J,Matei Daniela E,Li Yong,Sun Kaiming,Luptakova Katarina,Matulonis Ursula A,Monk Bradley J

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Cancer statistics, 2018;Seigel;CA Cancer J Clin,2018

2. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer;McMeekin;Gynecol Oncol,2004

3. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer;Alvarez;Gynecol Oncol,2016

4. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy;Matulonis;Cancer,2016

5. Limitations to the use of carboplatin-based therapy in advanced ovarian cancer;Fotopoulou;Eur J Cancer Suppl,2014

Cited by 403 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database;Journal of Gynecologic Oncology;2025

2. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

3. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16

4. IdentifiHR: predicting homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression;2024-08-16

5. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-08-12